Compare Medpace Holdings Inc (MEDP) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Petróleo Brasileiro SA — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Petróleo Brasileiro SA trades at $25.26 (market cap $151.94B). The key difference: Petróleo Brasileiro SA is far larger — about 9× Medpace Holdings Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Petróleo Brasileiro SA for 25 Days on average.
| MEDP | PBR | |
|---|---|---|
Market Cap | $16.82B | $151.94B |
Volume | 223,093 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $630.19 | $24.69 |
52-Week Low | $393.42 | $11.54 |
Typical Hold Time | 14 Days | 25 Days |
Enterprise Value | $16.44B | $212.36B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Petrobras (PBR) trades at $25.30, up 5.46% in the past 24 hours, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 6.24, net income margin of 24.52%, and ROE of 30.77%. Recent developments include new oil discoveries and platform deployments that support production growth.
The outlook remains positive with revenue projected to grow from $89.2B in 2025 to $104.2B in 2026. Risks include capital expenditure pressures and political exposure in Brazil. Analyst consensus is bullish with 50% buy ratings and a $22.33 price target, though the current price exceeds this target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
